Search results: (10000)
News Comparison of Dabigatran and Vitamin K Antagonists in Patients with Atrial Fibrillation in Real-World Practice
The final 3-year results of the GLORIA-AF study conducted in real-world practice with patients newly diagnosed with atrial fibrillation show a lower incidence of major bleeding and lower overall mortality with comparably effective prevention of cerebrovascular accidents and myocardial infarction when administering dabigatran compared to vitamin K antagonists (VKAs).
News VIDEO: Antibiotic Treatment of Infections Caused by MDR Bacteria – Seminar Recording
Recording of a professional seminar on the topic of infections caused by MDR bacteria, which took place on November 2, 2021, at the Medical House in Prague.
News Candesartan is beneficial in heart failure with mildly reduced ejection fraction
Analysis of data from the CHARM study showed that in patients with heart failure with mildly reduced ejection fraction (HFmrEF 0.40–0.49), candesartan compared to placebo reduces the risk of death from cardiovascular (CV) causes or hospitalization for heart failure similarly to patients with reduced ejection fraction (HFrEF < 0.40).
News Effectiveness of the Venetoclax/Rituximab Combination in the Treatment of CLL – 5-Year Follow-Up Data
At the virtual 62nd Annual Meeting of the American Society of Hematology (ASH), updated results of a clinical evaluation of the treatment of patients with refractory/relapsed chronic lymphocytic leukemia (R/R CLL) using venetoclax in combination with rituximab were presented.
News Effectiveness of Idarucizumab Reversal Effect
It is, of course, a great advantage if doctors have a specific substance available that counteracts the effect of oral anticoagulants in urgent need. Idarucizumab is a humanized monoclonal antibody that binds dabigatran with high affinity. The drug was approved for clinical use based on an interim analysis of the results of 90 patients enrolled in the RE-VERSE AD study. What conclusions were drawn based on the results of the entire study population?
News Prognostic Model MSKCC in Patients with Metastatic Renal Carcinoma Treated in 1st Line with Sunitinib
A study by Czech authors published in 2020 demonstrated the usefulness of the MSKCC (Memorial Sloan Kettering Cancer Center) model in the prognostic stratification of patients with metastatic renal carcinoma (mRCC) treated with sunitinib in the 1st line. Additionally, a significant difference was found between the outcomes achieved in patients with intermediate risk who had one or two risk factors.
News Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing worldwide, and the combination of both diseases significantly worsens the prognosis of patients. One of the main causes of increased mortality in these patients is macrovascular complications of DM2. The burden on the cardiovascular system is even greater with the concurrent occurrence of chronic heart failure.
News Hereditary Angioedema as a Clinical Picture of Excessive Activation of the Kinin Cascade – Case Report
Painful and potentially life-threatening swellings are characteristic of hereditary angioedema (HAE), a rare genetically determined disease. Dutch authors present in a recently published review the case report of a young woman with a life-threatening laryngeal swelling.
News Proton Therapy and Its Results in the Treatment of Bilateral Breast Cancer
Breast cancer is the most common malignant tumor disease in women, and its incidence sharply increases after the age of 50. Although its incidence shows a continuously increasing trend, the development of mortality is more favorable. Thanks to nationwide screening and more successful therapy, mortality has long been stable, even slightly decreasing. A relatively rare variant of this oncological disease is primary synchronously detected bilateral breast cancer (PSBBC). Experts from the Proton Therapy Center in Prague are focusing on the use of proton radiotherapy in the treatment of this clinical entity.
News Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin
Authors of the British study SUGAR-DM-HF published in February 2021 examined whether empagliflozin reduces left ventricle (LV) volume in patients with type 2 diabetes mellitus (DM), prediabetes, and heart failure with reduced ejection fraction (EF). This favorable reverse remodeling of the LV could be a mechanism through which empagliflozin achieves reduced hospitalization rates for heart failure and overall mortality in these patients.
News Calculator Naxiva - Application for Easy Prescription of Medical Cannabis Extracts
The new Calculator Naxiva application, specifically designed for doctors prescribing medical cannabis, allows for a simple conversion of its doses to the Naxiva Panaxol extract. Quickly and easily, the required amount of extract for a particular patient can be calculated.
News FOLFOXIRI and Panitumumab in mCRC Treatment – Improvement in Treatment Response and Metastasis Resectability
For patients with metastatic colorectal cancer (mCRC) who are able to undergo intensive treatment, the FOLFOX (5-fluorouracil/leucovorin, oxaliplatin) or FOLFIRI (5-fluorouracil/leucovorin, irinotecan) regimens combined with monoclonal antibodies represent the standard first-line treatment. The FOLFOXIRI regimen, which is another option, was developed to further enhance the efficacy of chemotherapy. The German oncologists' VOLFI study investigated the effectiveness of combining targeted therapy and triplet chemotherapy compared to chemotherapy alone in previously untreated patients with mCRC without RAS oncogene mutation.
News How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?
In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing skeletal events in patients with multiple myeloma or solid tumors (excluding breast and prostate cancer) and bone metastases was evaluated. An ad hoc analysis of this study then involved only a subgroup of patients with solid tumors.
News Factors Predicting Longer Survival in Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil
A recently published non-interventional analysis evaluated overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) with favorable prognostic factors before initiating treatment with trifluridine/tipiracil compared to patients with unfavorable factors. It also identified which specific prognostic factors are favorable in terms of therapy effectiveness.
News Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5
One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized patients with COVID-19 infection during the period of predominant omicron variants including subvariants BA.4 and BA.5 has provided real-world data confirming the position of this antiviral in the first line of treatment for patients with mild to moderately severe SARS-CoV-2 infection and a high risk of severe disease.
News Prevalence and Incidence of Age-Related Macular Degeneration in Europe – Current Overview and Trend Analysis
A comprehensive review article by authors from Bonn, Germany, published late last year in the British Journal of Ophthalmology, provides current data and estimates of the incidence and prevalence of age-related macular degeneration in Europe. Here is a brief summary of the key findings from this latest analysis.
News What can we base the decision on for the choice of initial treatment modality for CLL?
We now have a range of highly effective treatment options for patients with chronic lymphocytic leukemia (CLL). New drugs have significantly contributed to improved overall survival (OS). However, there are still questions about the most appropriate treatment regimen or criteria for choosing the initial therapeutic modality. Some of these questions are posed—and answers sought—by Professor John F. Seymour from the University of Melbourne in his recent communication.
News What situations can arise in PBC treatment with obeticholic acid? Answers provided by case studies from real practice at CKTCH
The Hradec Gastroenterology Days 2023 were traditionally held in March at the Educational Center of the Faculty of Medicine, Charles University, in the area of University Hospital Hradec Králové. The expert program included a lecture by MUDr. Libuše Husová, Ph.D., from the Cardio-surgical and Transplant Surgery Center Brno (CKTCH), who highlighted various situations that can arise during the treatment of primary biliary cholangitis (PBC) with three case studies.
News Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?
The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.
News Meta-analysis of the Metabolic Effects of Second-generation Antipsychotics
Second-generation antipsychotics used in the therapy of schizophrenia exhibit varying metabolic profiles. A recently conducted meta-analysis by Italian authors investigated the impact of second-generation antipsychotics on weight gain, BMI, lipid spectrum, and glycemia.
News Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery
Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial cardiac surgery associated with an increased risk of thromboembolic events or death? Authors of a Swedish observational study published last year aimed to answer this question.
News Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer
The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine compared to trastuzumab significantly improves invasive disease-free survival in patients with HER2-positive early breast cancer and residual invasive disease after prior treatment. A post hoc analysis of this study was published in the journal Cancer, focusing on patient-reported outcomes related to quality of life during and after treatment.